JP2025511713A5 - - Google Patents

Info

Publication number
JP2025511713A5
JP2025511713A5 JP2024559144A JP2024559144A JP2025511713A5 JP 2025511713 A5 JP2025511713 A5 JP 2025511713A5 JP 2024559144 A JP2024559144 A JP 2024559144A JP 2024559144 A JP2024559144 A JP 2024559144A JP 2025511713 A5 JP2025511713 A5 JP 2025511713A5
Authority
JP
Japan
Prior art keywords
heavy chain
sequence
sequence numbers
antibody
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511713A (ja
Filing date
Publication date
Priority claimed from PCT/CN2022/085838 external-priority patent/WO2023193239A1/en
Application filed filed Critical
Publication of JP2025511713A publication Critical patent/JP2025511713A/ja
Publication of JP2025511713A5 publication Critical patent/JP2025511713A5/ja
Pending legal-status Critical Current

Links

JP2024559144A 2022-04-08 2023-04-10 抗ｃｄ２８抗体及びその使用方法 Pending JP2025511713A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/085838 2022-04-08
PCT/CN2022/085838 WO2023193239A1 (en) 2022-04-08 2022-04-08 Anti-cd28 antibodies and methods of use thereof
PCT/CN2023/087277 WO2023193817A1 (en) 2022-04-08 2023-04-10 Anti-cd28 antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2025511713A JP2025511713A (ja) 2025-04-16
JP2025511713A5 true JP2025511713A5 (enExample) 2026-04-17

Family

ID=86332084

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559144A Pending JP2025511713A (ja) 2022-04-08 2023-04-10 抗ｃｄ２８抗体及びその使用方法

Country Status (11)

Country Link
US (1) US20250257133A1 (enExample)
EP (1) EP4504787A1 (enExample)
JP (1) JP2025511713A (enExample)
KR (1) KR20250008811A (enExample)
CN (1) CN120112552A (enExample)
AU (1) AU2023250992A1 (enExample)
CA (1) CA3255415A1 (enExample)
IL (1) IL316065A (enExample)
MX (1) MX2024012474A (enExample)
TW (1) TW202409082A (enExample)
WO (2) WO2023193239A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115279796A (zh) * 2020-01-23 2022-11-01 天演药业(瑞士)公司 具有Fc突变的异二聚蛋白质
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
CN120904324A (zh) * 2024-04-30 2025-11-07 惠和生物技术(上海)有限公司 抗cd28抗体及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5948893A (en) * 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
PT2171060E (pt) * 2004-11-11 2013-11-18 Theramab Llc Anticorpo anti-cd28 superagonista
US7585960B2 (en) * 2005-05-11 2009-09-08 Theramab Gmbh Nucleic acids encoding superagonistic anti-CD28 antibodies
AU2015202447B2 (en) * 2008-07-18 2017-01-19 Bristol-Myers Squibb Company Compositions monovalent for cd28 binding and methods of use
US9382329B2 (en) * 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
WO2014120916A1 (en) * 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
IL272696B2 (en) * 2017-08-21 2025-01-01 Adagene Inc Dynamic human heavy chain antibody libraries
WO2019148445A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
CA3095076A1 (en) 2018-03-29 2019-10-03 Adagene Inc. Anti-pd-l1 antibodies and use thereof
IL279354B1 (en) 2018-06-21 2026-02-01 Regeneron Pharma Bispecific antibodies against psma and against cd28 and their uses
CN115279796A (zh) 2020-01-23 2022-11-01 天演药业(瑞士)公司 具有Fc突变的异二聚蛋白质
JP7789002B2 (ja) * 2020-01-29 2025-12-19 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｃｄ２８シングルドメイン抗体ならびにその多価および多重特異性の構築物
AU2021295549A1 (en) * 2020-06-23 2022-11-24 F. Hoffmann-La Roche Ag Agonistic CD28 antigen binding molecules targeting Her2
CA3192204A1 (en) * 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions

Similar Documents

Publication Publication Date Title
JP7596450B2 (ja) 活性化可能抗体ならびにその作製及び使用方法
JP2025511713A5 (enExample)
EP2609112B1 (en) Activatable bispecific antibodies
JP2021511808A5 (enExample)
CN116419925A (zh) 受限的条件激活的结合蛋白
US12428494B2 (en) Compositions targeting prostate-specific membrane antigen and methods for making and using the same
JP2025160226A (ja) Ｆｃ変異を有するヘテロダイマータンパク質
IL298815A (en) Bispecific compositions targeting HER-2 and methods for their preparation and use
US12590159B2 (en) Compositions targeting epidermal growth factor receptor and methods for making and using the same
JP2025509272A5 (enExample)
JP2024542978A5 (enExample)
US20250333539A1 (en) Activatable antigen-binding protein constructs and uses of the same
JP7855148B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）を標的とする組成物、並びにそれを作製及び使用するための方法
WO2024213109A1 (en) Masked antibodies, libraries and methods of use
US20250326847A1 (en) Activatable anti-ctla4 antibodies for treating cancer
NZ767462B2 (en) Anti-ctla4 antibodies and methods of making and using the same
NZ767462A (en) Anti-ctla4 antibodies and methods of making and using the same
Gerspach Activatable bispecific antibodies The current invention relates to bispecific antibodies wherein the binding affinity to one of the two antigens is reduced and which can be activated by tumor-or inflammation-tissue/disease specific proteases (eg tumor-or inflammation-specific proteases); and the preparation and use of such bispecific antibodies.